Mupirocin

Nasal
Eradication of nasal colonisation with Staphylococci aureus

Topical/Cutaneous
Secondary skin infections

Topical/Cutaneous
Bacterial skin infections, Impetigo

Hypersensitivity.

Patient with extensive burns or open wounds. Not indicated for treatment of pressure sores. Renal impairment. Children and elderly. Pregnancy and lactation.

Significant: Hypersensitivity, systemic allergic reactions (e.g. angioedema, urticaria, generalised rash), cutaneous sensitisation reaction or severe local irritation; fungal or bacterial superinfection (prolonged use).
Gastrointestinal disorders: Nausea, dysgeusia.
General disorders and administration site conditions: Application site reactions (e.g. localised burning, stinging or tingling sensation, localised pain).
Nervous system disorders: Headache.
Respiratory, thoracic and mediastinal disorders: Rhinitis, respiratory congestion, pharyngitis, cough, nasal mucosa reactions.
Skin and subcutaneous tissue disorders: Pruritus, erythema, skin dryness, rash, contact dermatitis.

Nasal/Topical: B

Avoid contact with eyes and mucous membranes.

Description:
Mechanism of Action: Mupirocin, an antibiotic produced by fermentation of Pseudomonas fluorescens, inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl transfer-ribonucleic acid (tRNA) synthetase. It has bacteriostatic effects at minimum inhibitory concentrations and bactericidal effects at higher concentrations.
Synonyms: Pseudomonic acid, trans-Pseudomonic acid.
Pharmacokinetics:
Absorption: Minimally absorbed systemically through intact skin.
Distribution: Plasma protein binding: >97%.
Metabolism: Rapidly metabolised to its inactive metabolite, monic acid.
Excretion: Via urine (as inactive monic acid metabolite). Elimination half-life: 17-36 minutes.

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 446596, Mupirocin. https://pubchem.ncbi.nlm.nih.gov/compound/Mupirocin. Accessed May 26, 2022.

Store below 25°C. Do not freeze.

Topical Antibiotics

R01AX06 - mupirocin ; Belongs to the class of other nasal preparations for topical use.
D06AX09 - mupirocin ; Belongs to the class of other topical antibiotics used in the treatment of dermatological diseases.

Anon. Mupirocin. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 06/04/2022.

Anon. Mupirocin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 06/04/2022.

Bactroban 2% Cream (Beecham Group plc). MHRA. https://products.mhra.gov.uk. Accessed 06/04/2022.

Bactroban 2% Nasal Ointment (Beecham Group plc). MHRA. https://products.mhra.gov.uk. Accessed 06/04/2022.

Bactroban 2% Ointment (Beecham Group plc). MHRA. https://products.mhra.gov.uk. Accessed 06/04/2022.

Bactroban Cream (Beecham Group plc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 06/04/2022.

BNM Group. Mupider 2% Ointment data sheet 10 February 2020. Medsafe. http://www.medsafe.govt.nz. Accessed 06/04/2022.

Buckingham R (ed). Mupirocin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/04/2022.

Joint Formulary Committee. Mupirocin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/04/2022.

Medicianz Healthcare Limited. Mupirocin Nasal Ointment Medsurge data sheet 16 January 2020. Medsafe. http://www.medsafe.govt.nz. Accessed 06/04/2022.

Mupirocin Ointment (Glenmark Pharmaceuticals Inc., USA). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 06/04/2022.

Pirnuo Cream (Glenmark Pharmaceuticals Inc., USA). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 06/04/2022.